
Entac Medical
Digital health company developing wearable devices that use predictive analytics/ai to biological acoustic signals to predict downstream patient adverse events, improving patient outcomes, preventing hospital readmissions and reducing the cost of care.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor investor | €0.0 | round |
investor | €0.0 | round | |
investor investor | €0.0 | round | |
investor | €0.0 | round | |
investor investor | €0.0 | round | |
N/A | €0.0 | round | |
* | N/A | Early VC | |
Total Funding | 000k |
Related Content
Entac Medical, Inc. operates as a digital health company, founded in 2011 by Buddy Lyons and Dr. John Cromwell, and is headquartered in Germantown, Tennessee. The company focuses on developing wearable medical devices that utilize predictive analytics and artificial intelligence to monitor biological acoustic signals. This technology is engineered to anticipate adverse patient events, aiming to mitigate risks, improve outcomes, and lower hospital readmission rates.
The company's core technology is based on audio spectral analysis. Its flagship product, PrevisEA™, is a non-invasive, disposable, self-contained device designed to predict the likelihood of postoperative ileus (POI), a temporary paralysis of the gastrointestinal tract that can occur after surgery. By capturing and analyzing bowel sounds through an abdominal microphone, PrevisEA™ can stratify a patient's risk for developing the condition within 12 hours post-operation, enabling surgeons to make more timely decisions about patient care, such as re-feeding and discharge timing. In clinical settings, the device has shown high accuracy, with 95% specificity and 83% sensitivity. POI is a significant complication, affecting a substantial number of surgical patients and contributing to longer hospital stays and increased healthcare costs, estimated at $10-$15 billion annually in the US.
Entac Medical's business model is business-to-business (B2B), primarily serving hospitals, clinics, and other healthcare institutions in the United States and Europe. Revenue is generated through the direct sale of its devices to these facilities. The company has secured funding to support its product development and market expansion efforts, including a Series A round in 2016 and a Series A2 round in 2018, both led by Innova Memphis. The leadership team includes Buddy Lyons as CEO, who brings over 25 years of experience in healthcare investing and startup operations, and Dr. John Cromwell as CMO/CTO, the inventor of the company's core predictive analytic technologies and a clinical professor of surgery.
Keywords: predictive analytics, digital health, wearable medical devices, postoperative care, gastrointestinal impairment, acoustic signal analysis, postoperative ileus, patient monitoring, risk stratification, hospital readmissions, medical device technology, surgical outcomes, healthcare AI, non-invasive diagnostics, PrevisEA, Buddy Lyons, John Cromwell, Innova Memphis, audio spectral analysis, predictive medicine